Document is current
Any future updates will be listed below
-
Authors
Hara, Takuto
Suzuki, Kotaro
Okamura, Yasuyoshi
Chiba, Koji
Sato, Ryo
Matsushita, Yuto
Tamura, Keita
Ishikawa, Gaku
Otsuka, Atsushi
Miyake, Hideaki
- License Information
-
More Information
Article History
Received: 4 June 2024
Accepted: 17 September 2024
First Online: 30 October 2024
Declarations
:
: This multicenter retrospective observational study was conducted in Hyogo and Shizuoka Prefectures, Japan. It enrolled aRCC patients who were treated with lenvatinib plus pembrolizumab as first-line therapy. All procedures were conducted in accordance with the 1964 Helsinki Declaration and approved by the Ethics Committee of our institutions. The need to obtain informed consent for involvement in this study from all included patients was waived due to its retrospective manner.
: Hideaki Miyake received honoraria from Astellas, AstraZeneca, Bayer, Eisai, Janssen, Merck, MSD, Nippon-Shinyaku, Novartis, Ono, Pfizer, Sanofi and Takeda. Hideaki Miyake received research funding from MSD, Pfizer and Ono.
